Notably, targeted degradation of CDK12/13 with YJ1206 treatment was evaluated in combination with ICB in a broad range of cancer types, including prostate cancer, melanoma, colon cancer, and lung cancer, where it significantly delays tumor growth and enhances ICB efficacy. The gene discussed is CDK12; the disease is prostate cancer.